loader image

LATVIAN

BIOMEDICAL

RESEARCH AND STUDY CENTRE


RESEARCH AND EDUCATION IN BIOMEDICINE FROM GENES TO HUMAN

Project Title: „Identification of molecular determinants associated with the risk for various COVID-19 long term effects: a comprehensive cohort-based study in Latvian population. (POST-COVID-TRACK)”

Funding: European Regional Development Fund (ERDF), Measure 1.1.1.1 “Support for applied research”

Project No.: 1.1.1.1/21/A/029

Period: 1 January 2022 – 30 November 2023

Project costs: 500 000,00 EUR

Principle Investigator: Dr. biol.  Jānis Kloviņš

Cooperation partner: Pauls Stradiņš Clinical University Hospital

Project summary:

SARS-CoV-2 infection is a pandemic causing serious health and life threats at its acute phase and impacting the long-term health of post-COVID-19 patients, including multiorgan damage and various disease outcomes. It is estimated that around 80% of COVID-19 patients develop at least one of the long-term outcomes, while the detailed understanding of how infection and following recovery process is impacting these effects is not known. The goal of the project is to identify factors predicting and affecting the development of COVID-19 long-term effects by combining the omics-based data and clinical information in various cohorts of Latvian COVID-19 patients by a novel coronavirus with the impact on various concomitant diseases causing multiorgan damage and various disease outcomes. We will explore different omics-based data focusing on longitudinal changes in gene expression, metabolome, and cell-type-specific activity in samples obtained from COVID-19 patients at acute disease state and during the recovery period. We will use the large existing cohort of COVID-19 patients to access the most frequent post-covid symptoms and perform targeted recruitment of patients in specific disease areas to reach out for rare but more severe complications. We aim to increase the knowledge on molecular mechanisms leading to the development of COVID-19 related outcomes and identify new biomarkers that can be used for prevention and therapy optimization.

Information published 03.01.2022.

Progress of the project:

1 January 2022 – 31 March 2022

In collaboration with Latvian Centre for Disease Prevention and Control and Genome State registry responsible for ID decoding, we are collecting the clinical data of COVID-19 patients involved in the Genome Database of Latvian Population during the National Research Program framework to Mitigate Consequences of COVID-19 (July 2020-March 2021) to acquire information about the most frequent post-COVID syndromes and further organize the follow-up procedures. For the establishment of disease targeted post-COVID-19 patient cohorts sample and data collection strategy is being developed considering the specific processing and storage conditions needed for expected downstream analysis (e.g. spatial transcriptomics, single-cell transcriptomics). Meanwhile, the optimal protocol for urine sample pre-treatment for metabolomics analysis is being developed.

Information published 31.03.2022.

Progress of the project

1 April 2022 – 30 June 2022

In collaboration with Pauls Stradiņš Clinical University Hospital we have initiated sample collection from patients with long-term health nephrological, neurological and pulmonary issues associated with COVID-19. For non-standard (bronchoalveolar lavage fluid, cerebrospinal fluid, and kidney biopsy) samples that will be used in further analysis, such as spatial and single-cell transcriptome sequencing, we have established specific protocols for collection, processing, and preservation. We are continuing clinical data acquisition and processing from Latvian Centre for Disease Prevention and Control and Genome State registry, as well as existing patient cohort expansion from Latvian national biobank. Previously and newly obtained omics, metagenome and full genome sequencing data are being gathered and preliminary data analysis has been launched.

Information published 30.06.2022.